April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Intravitreal Bevacizumab for the Treatment of Diabetic Papillopathy
Author Affiliations & Notes
  • Sung Jae Yang
    Ophthalmology, Gangneung Asan Medical Center, Gangneung, Republic of Korea
  • Ju Byung Chae
    Ophthalmology, Chung Buk National University Hospital, Cheong Ju, Republic of Korea
  • Young Hee Yoon
    Ophthalmology-Coll of Med,
    Univ of Ulsan College, Seoul, Republic of Korea
  • Joo Yong Lee
    Department of Ophthalmology, Asan Medical Center, Seoul, Republic of Korea
  • June-Gone Kim
    Ophthalmology,
    Univ of Ulsan College, Seoul, Republic of Korea
  • Footnotes
    Commercial Relationships  Sung Jae Yang, None; Ju Byung Chae, None; Young Hee Yoon, None; Joo Yong Lee, None; June-Gone Kim, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 3898. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sung Jae Yang, Ju Byung Chae, Young Hee Yoon, Joo Yong Lee, June-Gone Kim; Intravitreal Bevacizumab for the Treatment of Diabetic Papillopathy. Invest. Ophthalmol. Vis. Sci. 2011;52(14):3898.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To present the effect of intravitreal bavacizumab injection for the treatment of diabetic papillopathy.

Methods: : Retrospectively reviewed the medical records of 3 consecutive patients who treated with intravitreal injection of bevacizumab for the treatment of diabetic papillopathy.

Results: : Patient one was a 73-year-old woman with 15-year history of type II diabetes mellitus, her vision of left eye improved from 0.05 to 0.32 6 weeks after intravitreal bevacizumab injection. Patient two was a 47-year-old woman with 8-year history of type II diabetes mellitus, her vision of right eye was 0.16. A week after intravitreal injection of bevacizumab, vision impoved to 0.32. Patient three was a 46-year-old woman with 2-year history of type II diabetes mellitus. Her vision of left eye was 0.63. Two week after injection her vision was improved to 0.8. One month after injection blurring of disc margin disappeared. There were resolution of disc swelling and/or leakage from fluorescein angiography within 2~6 weeks in all three cases. There was no injection related complication.

Conclusions: : The visual acuity of all the three patients improved within few weeks. Intravitreal bevacizumab injection for the treatment of diabetic papillopathy seems effective and safe. And intravitreal bevacizumab injection can be one of options for the treatment of diabetic papillopathy and shortened the duration of symptom.

Keywords: optic disc • diabetes 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×